Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite ...

Prescriptions for GLP-1 receptor agonists in cancer patients have increased despite lack of clinical guidance. The overall ...

Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years, but patient access has been a ...

Researchers compared the incidence of infection-related outcomes and hypoglycemia across antidiabetic drug classes in patients with inflammatory arthritis and diabetes.

Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking ...

Coverage of the drugs will expand to Medicare patients starting next year, and some lower prices will also be phased in for ...

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful ...

By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

GLP-1RA use, compared with basal insulin and DPP-4i use, was associated with lower risks for IBD and hospitalization in type 2 diabetes.

Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.